2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3
2004
Care of patients after esophagectomy.
Mackenzie D, Popplewell P, Billingsley K. Care of patients after esophagectomy. Critical Care Nurse 2004, 24: 16-29; quiz 30-1. PMID: 15007889, DOI: 10.4037/ccn2004.24.1.16.Peer-Reviewed Original Research
2002
Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia
Dominitz J, Maynard C, Billingsley K, Boyko E. Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia. Medical Care 2002, 40: i-14. PMID: 11789626, DOI: 10.1097/00005650-200201001-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBlack or African AmericanCarcinoma, Squamous CellCardiaChemotherapy, AdjuvantCohort StudiesEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionHealth Services AccessibilityHealth Services ResearchHospitals, VeteransHumansMaleProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisUnited StatesVeteransWhite PeopleConceptsSquamous cell carcinomaDistal esophageal cancerSurgical resectionBlack patientsRadiation therapyEsophageal cancerEsophageal adenocarcinomaEqual‐access medical systemWhite veteransVeterans Affairs Medical CenterBlack male veteransDistal esophageal adenocarcinomaSurvival of veteransRetrospective cohort studySurvival of patientsCohort studyGastric cardiaDistal esophagusSimilar oddsCell carcinomaCancer survivalMedical CenterInvasive proceduresLower oddsSimilar survival
2001
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley K, Maynard C, Schwartz D, Dominitz J. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 2001, 92: 1272-1280. PMID: 11571743, DOI: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsOperable esophageal carcinomaTrimodality therapyEsophageal carcinomaPerioperative mortalityDistal esophageal tumorsOutpatient clinic filesOutcomes of patientsRetrospective cohort studyOverall perioperative mortalityFavorable prognostic factorPredictors of survivalAbsence of metastasesMain outcome measuresPatient Treatment FileRecord Locator SystemType of treatmentHealth care systemInduction chemoradiotherapyMidesophageal tumorsNeoadjuvant chemoradiotherapyCohort studyMedian survivalOverall survivalPatient ageSurgical therapy